inhaled type I interferon: The interventional arm includes inhaled interferon (9.6 MUI x2/d for 48 hours, then 9.6 MUI x1/d for 8 to 16 days or discharge), in addition to standard care. In phase B, maximum treatment duration is 8 days.
WFI water nebulization: The interventional arm includes a WFI water nebulization comparator.
Study summary
COVID-19 is causing a serious viral pandemic in terms of health and social impact. To date, no treatment has yet demonstrated Strong efficacy in treating the infectious disease (COVID-19). Pulmonary administration of Interferon (IFN) type I is a therapeutic strategy with high potential,due to higher local concentrations and minimal adverse effects. Type I interferons (including IFN-α and IFN-β) are antiviral defence cytokines and also have the potential to negatively modulate IFN Type II and IL-6 dependent cytokine storm, the latter being induced in the late forms of COVID-19. In vitro, IFN-β were more effective on COVID-19 than IFN-α. In existing preliminary studies, only patients receiving IFN type I modulators have a decrease in viral carriage and a rapid reversal. The purpose of this project is to assess in hospitalized patients with oxygen for COVID 19, the clinical efficacy on oxygen requirements of the addition of inhaled Interferon type I compared to the control arm .
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Age ≥ 18 years old
* Patient with laboratory-confirmed SARS-CoV-2 infection as determined by PCR \< 96 h (at initial diagnosis or persistent carriage \<96 h)
* Hospitalized patient with COVID-19 requiring oxygen therapy
And targeting in phase B :
* Patients under oxygen therapy such as nasal cannula/mask or non-invasive ventilation with paO2/FiO2 \> 200 mmHg.
* Patients hospitalized for less than 7 days.
* Patients with symptoms for less than 10 days or RT-PCR (\<96h) with Cycle Treshold \< 25.
* Social security coverage
* signed informed consent (by patient or their legally authorized representative)
Exclusion Criteria:
* Hypersensitivity to natural or recombinant interferon-ß
* Hypersensitivity to human albumin or mannitol
* Recent suicide attempt
* Decompensation of liver failure
* age \< 18 years
* Pregnant or nursing.
* Patients managed on an outpatient basis (i.e. not initially hospitalized).
* Parenteral IFN treatment. In periode B, addition of new exclusion criteria
* Patients with kidney transplant
* Immunocompromised patients
* Patients with severe systemic disease constantly threatening their vital prognosis (ASA ≥ IV: e.g. severe ARF, advanced cancer pathology, recent myocardial IDM, severe valvular dysfunction, dependence on parenteral nutrition on central line, shock, sepsis, trauma, ...).
* Patients in septic shock.
* Patients with documented fungal infection.
* Patients on mechanical ventilation.
* Patients hospitalized for COVID-19 for more than 7 days.
Primary outcome measure(s)
oxygen requirement score at day 0 — day 0 oxygen requirement score at day 0
oxygen requirement score at day 15 — day 15 oxygen requirement score at day 15
Variation oxygen requirement score between day 0 and day15 — at day 15 Variation oxygen requirement score between day 0 and day15
Trial sites (7)
Facility
City
Region
Status
CH d'Abbeville
Abbeville
France
CHU Amiens
Amiens
France
CH Compiègne-Noyon
Compiègne
France
CH de l'Arrondissement de Montreuil-sur-mer
Rang-du-Fliers
France
CH de Saint-Quentin
Saint-Quentin
France
CH de Tourcoing
Tourcoing
France
CH de valenciennes
Valenciennes
France
More Centre Hospitalier Universitaire, Amiens trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
